Is it reasonable to offer APBI in an obese patients with large breasts and N1mi disease?

Most published data with micromets and no nodal RT (most are small series) show a risk of regional recurrence is very low and varies from 0 to 5%. For that reason, micromets would not be contraindications to APBI because if the same patient has a mastectomy done, we would not offer any RT for node.